^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SON-DP

    i
    Other names: SON-DP
    Associations

    News

    Trials
    Company:
    Qurgen
    Drug class:
    Transcription factor modulator
    Associations

    News

    Trials
    12ms
    SON-DP in Participants with Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=96, Recruiting, Qurgen Inc.
    New P1 trial
    |
    SON-DP
    almost2years
    A First-in-Human, Open-label, Phase Ia Dose Escalation Study of SON-DP in subjects with advanced/metastatic solid tumors that have relapsed or are refractory/intolerant to standard of care therapies (ACTRN12623000202662)
    P1, N=48, Withdrawn, Qurgen Australia Pty Ltd | Recruiting --> Withdrawn
    Trial withdrawal • Tumor mutational burden • Metastases
    |
    TMB (Tumor Mutational Burden) • POU5F1 (POU Class 5 Homeobox 1)
    |
    SON-DP
    2years
    A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, Qurgen Inc. | Phase classification: P1a/1b --> P1
    Phase classification
    |
    SON-DP
    over2years
    A First-in-Human, Open-label, Phase Ia Dose Escalation Study of SON-DP in subjects with advanced/metastatic solid tumors that have relapsed or are refractory/intolerant to standard of care therapies (ACTRN12623000202662)
    P1, N=48, Recruiting, Qurgen Australia Pty Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Tumor mutational burden • Metastases
    |
    TMB (Tumor Mutational Burden) • POU5F1 (POU Class 5 Homeobox 1)
    |
    SON-DP